Methotrexate shows promise for treating juvenile scleroderma

01/8/2013 | PhysiciansBriefing.com

More than 70% of juvenile localized scleroderma patients who took oral methotrexate were in clinical remission for a mean of 25 months, while 27.1% experienced remission while taking the drug, according to an Italian study in the Journal of the American Academy of Dermatology. Generally mild side effects were reported by 48.3% of respondents, but they didn't cause the patients to stop the medication.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR CLINICAL RESEARCH - 14000003MB
Abbott
Santa Clara, CA
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA